CJC-1295 and Ipamorelin: The Complete Stack Guide (Dosing, Benefits & Protocols)

If you have spent any time researching peptide therapy, you have almost certainly come across the pairing of CJC-1295 and Ipamorelin. It is one of the most widely prescribed peptide combinations in longevity and performance medicine — and for good reason. These two compounds work through complementary mechanisms to amplify growth hormone (GH) release in a way that is both effective and remarkably well-tolerated.

This guide covers everything: how each peptide works, why they are stacked together, standard dosing protocols, what results to expect, side effects, and practical guidance on reconstitution and injection technique.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous signal that tells your pituitary gland to secrete GH. Natural GHRH has a half-life of only a few minutes in plasma, which limits its therapeutic usefulness. CJC-1295 was engineered to be far more stable.

There are two versions you will encounter:

• CJC-1295 without DAC (also called Modified GRF 1-29): Half-life of approximately 30 minutes. Produces a clean, pulsatile GH release that closely mimics the body’s natural GH secretion pattern. This is the version typically used in the CJC-1295/Ipamorelin stack.
• CJC-1295 with DAC (Drug Affinity Complex): Half-life extended to approximately 8 days. Provides a sustained “bleed” of GH stimulation rather than discrete pulses. Less commonly paired with Ipamorelin because the prolonged stimulation can raise cortisol and prolactin in some individuals.

For stacking with Ipamorelin, the no-DAC variant is almost universally preferred. It produces discrete GH pulses, clears quickly, and has a cleaner hormonal side-effect profile.

What Is Ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue (GHS) and selective ghrelin receptor agonist. It belongs to a class of peptides known as GHRPs (growth hormone-releasing peptides), but it is widely regarded as the cleanest and most selective of the group.

Unlike older GHRPs such as GHRP-6 and GHRP-2, Ipamorelin does not cause significant elevations in cortisol or prolactin at standard doses. This makes it a far more targeted tool for GH augmentation. It works by binding to the ghrelin receptor (GHSR-1a), triggering the anterior pituitary to release a pulse of GH.

Ipamorelin also has a relatively short half-life of about two hours, which makes it ideal for timed, pulsatile dosing.

Why Stack CJC-1295 and Ipamorelin Together?

The synergy between these two peptides comes from the fact that they stimulate GH release through different but complementary pathways.

• CJC-1295 (no DAC) acts on the GHRH receptor, increasing the “amplitude” of each GH pulse — essentially making each pulse larger.
• Ipamorelin acts on the ghrelin receptor, increasing the “frequency” of GH pulses — triggering more pulses over time.

Used together, these two pathways create a synergistic effect — higher-amplitude GH pulses occurring more frequently — without the side effects of simply taking more of either compound individually. Clinical and preclinical data consistently show that the combination produces significantly greater GH and IGF-1 elevations than either peptide alone at equivalent doses.

The result is a GH release profile that closely mirrors the body’s natural pulsatile secretion — unlike exogenous recombinant HGH injections, which flood the bloodstream continuously and can desensitize GH receptors over time.

Benefits of the CJC-1295 / Ipamorelin Stack

The downstream effects of sustained, optimized GH and IGF-1 elevation include:

• Body Composition: GH stimulates lipolysis (fat breakdown) and supports muscle protein synthesis. Most protocols targeting body composition report 10–20+ lbs of fat loss and 3–8 lbs of lean muscle gain over a 4–6 month cycle, assuming appropriate diet and training.
• Sleep Quality: GH is secreted primarily during slow-wave (deep) sleep. Users frequently report improved sleep quality within the first 2–4 weeks of a protocol, with deeper, more restorative sleep cycles.
• Recovery: Elevated IGF-1 supports tissue repair and reduces recovery time from exercise, injury, and surgery. This makes the stack particularly popular among athletes and physically active individuals.
• Energy and Vitality: Many users notice increased energy levels and improved sense of well-being beginning in weeks 4–8 of a protocol.
• Cognitive Function: GH and IGF-1 receptors are expressed throughout the brain. Some users and clinicians report improved focus, mental clarity, and mood on long-term protocols.
• Skin and Connective Tissue: GH supports collagen synthesis, leading to improved skin elasticity and joint health over multi-month protocols.

Standard Dosing Protocol

Dosing varies by goal and individual tolerance, but the most commonly prescribed protocol is:

Standard nightly protocol

• CJC-1295 no DAC: 100–300 mcg
• Ipamorelin: 200–300 mcg
• Frequency: Once daily, administered 30–60 minutes before bed
• Timing: At least 2 hours after your last meal (food raises insulin, which blunts GH release)
• Cycle length: 3–6 months on, 1–2 months off

Advanced twice-daily protocol

Some clinicians prescribe two injections per day — one in the morning (fasted) and one before bed — for individuals with more aggressive body composition or recovery goals. At this frequency, doses are typically kept at the lower end of the range (100–200 mcg each peptide per injection) to avoid excessive IGF-1 elevation.

Escalation schedule

If new to peptide therapy, a common approach is to start at the low end and escalate:

• Weeks 1–2: 100 mcg CJC-1295 / 100 mcg Ipamorelin nightly
• Weeks 3–4: 200 mcg CJC-1295 / 200 mcg Ipamorelin nightly
• Week 5 onward: 200–300 mcg CJC-1295 / 200–300 mcg Ipamorelin nightly

Expected Timeline of Results

• Weeks 1–4: Improved sleep quality is often the first noticeable change. Some users also report slightly increased energy and appetite.
• Weeks 4–8: Faster workout recovery, improved muscle fullness, and the beginning of body composition shifts become noticeable.
• Weeks 8–16: More visible changes in body composition — increased lean mass, reduced body fat — particularly with consistent training and nutrition.
• Months 4–6: Full effects on skin quality, joint health, and sustained body composition improvements.

Side Effects

The CJC-1295/Ipamorelin stack has a favorable side-effect profile relative to exogenous HGH and older GHRP compounds, but it is not without risks.

Common (typically mild and transient)

• Injection site redness or mild irritation
• Transient facial flushing (“GH flush”) shortly after injection
• Water retention, particularly in the first few weeks
• Mild fatigue or dizziness shortly post-injection (typically resolves in 30 minutes)
• Increased hunger, especially at higher Ipamorelin doses (less pronounced than GHRP-6)

Less common

• Numbness or tingling in extremities (elevated IGF-1 effect, usually dose-dependent)
• Headache post-injection
• Elevated fasting glucose (GH has anti-insulin effects; those with insulin resistance should monitor)

Notably absent (compared to non-selective GHRPs): cortisol spikes, prolactin elevation, and significant appetite dysregulation. This is one of the key advantages of Ipamorelin over older peptides like GHRP-6 and GHRP-2.

Reconstitution and Storage

Both peptides arrive as lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BW) before use. Never use regular sterile water — BW contains 0.9% benzyl alcohol, which prevents microbial growth and significantly extends the usable lifespan of the reconstituted peptide.

Reconstitution steps

1. Wipe the rubber stopper of the peptide vial with an alcohol swab and allow it to air-dry.
2. Draw up 1–2 mL of bacteriostatic water into a syringe.
3. Insert the needle at an angle against the inside wall of the vial — let the water run slowly down the side, not directly onto the powder.
4. Gently swirl the vial (do not shake) until the powder is fully dissolved. The solution should be clear.
5. Store the reconstituted vial in the refrigerator at 2–8°C (35–46°F). Use within 28 days.

A common mixing ratio: add 2 mL bacteriostatic water to a 5 mg vial of each peptide, giving a concentration of 2.5 mg/mL (2,500 mcg/mL). At this concentration, a 200 mcg dose of Ipamorelin requires 0.08 mL (8 units on an insulin syringe).

Storage summary

• Lyophilized (unreconstituted): Room temperature, away from light. Stable for 12–24 months.
• Reconstituted: Refrigerated at 2–8°C. Use within 28 days. Never freeze.

Injection Technique

Both peptides are administered via subcutaneous (sub-Q) injection — into the fatty tissue just beneath the skin, typically the abdomen.

1. Use an insulin syringe (29–31 gauge, 0.5 inch needle).
2. Clean the injection site with an alcohol swab and allow it to dry.
3. Pinch a fold of skin at least 2 inches from the navel.
4. Insert the needle at a 45° angle and depress the plunger slowly.
5. Hold for a few seconds before withdrawing, then apply gentle pressure.
6. Rotate injection sites with each administration to avoid lipohypertrophy.

Both peptides can be drawn into the same syringe for a single daily injection, which is the most common clinical approach.

Who Is This Stack For?

The CJC-1295/Ipamorelin stack is commonly used by:

• Adults over 30 experiencing age-related GH decline, seeking to maintain muscle mass, reduce body fat, and improve energy
• Athletes and fitness enthusiasts focused on accelerated recovery and lean body composition
• Longevity and biohacking patients optimizing multi-system hormone levels
• Post-surgical recovery patients benefiting from GH-driven tissue repair
• Individuals with GH deficiency as a gentler alternative to exogenous HGH

The stack is generally not recommended for individuals under 21 (whose GH axis is still fully active), those with active cancers or a personal history of cancer (GH/IGF-1 can promote cell proliferation), pregnant or breastfeeding women, or those with uncontrolled diabetes or severe insulin resistance without close medical monitoring.

Regulatory Status

Both CJC-1295 and Ipamorelin remain unapproved by the FDA as finished drug products. They are classified as research chemicals, and neither has completed Phase III clinical trials for any therapeutic indication.

In the United States, both peptides have historically been available through 503A compounding pharmacies with a valid prescription. However, in 2024, the FDA moved to restrict compounded peptides, placing both CJC-1295 and Ipamorelin on its list of bulk drug substances that are not eligible for compounding. This has significantly curtailed their legal availability through traditional compounding channels as of 2025, though the landscape continues to evolve.

Patients should consult with a qualified healthcare provider familiar with peptide therapy to understand the current legal status in their jurisdiction and access options through legitimate medical channels.

Frequently Asked Questions

Can I mix CJC-1295 and Ipamorelin in the same syringe?

Yes. Both peptides are compatible in solution and are routinely drawn into a single insulin syringe for one subcutaneous injection. Many clinics also supply them as a pre-mixed blend in a single vial.

How long before I see results?

Sleep improvements often occur within the first 2–4 weeks. Body composition changes typically require 8–16 weeks of consistent use alongside appropriate training and nutrition.

Is this stack better than HGH?

Not necessarily “better” — different. Exogenous HGH provides a consistent, pharmacological dose of growth hormone. The CJC-1295/Ipamorelin stack works by amplifying your body’s own GH secretion in a pulsatile pattern. This preserves natural feedback loops, is generally considered safer for long-term use, and is significantly more affordable.

Do I need to cycle off?

Most protocols include an off period (typically 4–8 weeks after a 3–6 month cycle) to prevent receptor desensitization, though the clinical evidence on mandatory cycling is limited. Many longevity clinicians use continuous low-dose protocols without structured breaks.

Conclusion

CJC-1295 and Ipamorelin represent one of the most clinically refined peptide combinations available. By targeting two distinct arms of the GH secretion pathway simultaneously, they produce synergistic GH and IGF-1 elevations that neither peptide achieves alone — without the side-effect burden of older GHRPs or exogenous HGH.

For those seeking to optimize body composition, improve recovery, enhance sleep, and support healthy aging, this stack remains one of the most popular and well-characterized options in peptide medicine. As with all peptide therapies, working with a knowledgeable clinician is essential to ensure appropriate dosing, monitoring, and legal compliance in your region.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. CJC-1295 and Ipamorelin are unapproved research compounds. Consult a qualified healthcare professional before initiating any peptide therapy.